Pascal Vranckx

Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial

Ono M, Hara H, Kawashima H, Gao C, Wang R, Wykrzykowska JJ, Piek J, Garg S, Hamm C, Steg PG, Valgimigli M, Windecker S, Vranckx P, Onuma Y, Serruys P

August 5, 2022 | 10.4244/EIJ-D-21-00870

Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction!

Vranckx P, Valgimigli M

July 22, 2022 | 10.4244/EIJ-E-22-00004

Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score

Gragnano F, Jolly S, Mehta SR, Branca M, van Klaveren D, Frigoli E, Gargiulo G, Leonardi S, Vranckx P, Di Maio D, Monda E, Fimiani L, Fioretti V, Chianese S, Andò G, Esposito G, Sangiorgi G, Biondi-Zoccai G, Heg D, Calabrò P, Windecker S, Romagnoli E, Valgimigli M

December 17, 2021 | 10.4244/EIJ-D-21-00441

Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices

Chieffo A, Dudek D, Hassager C, Combes A, Gramegna M, Halvorsen S, Huber K, Kunadian V, Maly J, Møller J, Pappalardo F, Tarantini G, Tavazzi G, Thiele H, Vandenbriele C, Van Mieghem N, Vranckx P, Werner N, Price S

July 20, 2021 | 10.4244/EIJY21M05_01

Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes

Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys P, Hamm C, Steg PG, Heg D, Branca M, Jüni P, Windecker S, Valgimigli M

October 23, 2020 | 10.4244/EIJ-D-20-00145

Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial

Takahashi K, Chichareon P, Modolo R, Kogame N, Chang C, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen J, Wykrzykowska JJ, de Winter R, Hamm C, Steg PG, Stoll H, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys P

October 23, 2020 | 10.4244/EIJ-D-19-00498

Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial

Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang C, Kogame N, Spitzer E, Buszman P, van Geuns R, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabate M, Zmudka K, Rademaker-Havinga T, Tijssen J, Jüni P, Hamm C, Steg PG, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys P

April 3, 2020 | 10.4244/EIJ-D-19-00699

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Serruys P, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg PG, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

December 20, 2019 | 10.4244/EIJ-D-19-00202

Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial

Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang C, Tomaniak M, Asano T, Katagiri Y, van Geuns R, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber C, Sabate M, Iqbal J, Wykrzykowska JJ, Piek J, Spitzer E, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Serruys P

August 9, 2019 | 10.4244/EIJ-D-19-00184

Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial

Vranckx P, Valgimigli M, Windecker S, Steg PG, Hamm C, Jüni P, Garcia-Garcia H, Van Es G-A, Serruys P

November 20, 2016 | 10.4244/EIJY15M11_07

How should I treat this unusual anterolateral ST-elevation myocardial infarction with recurrent ventricular fibrillation and cardiac arrest?

Malik V, Safaa A, Clugston R, Noc M, Fister M, Vranckx P, Valgimigli M, Heidbuchel H

September 18, 2016 | 10.4244/EIJV12I7A153

Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration

Costa F, Adamo M, Ariotti S, Ferrante G, Navarese E, Leonardi S, Garcia-Garcia H, Vranckx P, Valgimigli M

February 12, 2016 | 10.4244/EIJY15M08_04

Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention

Vranckx P, Kalesan B, Stefanini G, Farooq V, Onuma Y, Silber S, de Vries T, Jüni P, Serruys P, Windecker S

June 19, 2015 | 10.4244/EIJV11I2A31

Gender, TIMI risk score and in-hospital mortality in STEMI patients undergoing primary PCI: results from the Belgian STEMI registry

Gevaert S, De Bacquer D, Evrard P, Convens C, Dubois P, Boland J, Renard M, Beauloye C, Coussement P, De Raedt H, de Meester A, Vandecasteele E, Vranckx P, Sinnaeve P, Claeys M

January 20, 2014 | 10.4244/EIJV9I9A184

A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients

Vranckx P, Verheugt F, de Maat MP, Ulmans V, Regar E, Smits P, ten Berg J, Lindeboom W, Jones R, Friedman J, Reilly P, Leebeek F

January 18, 2013 | 10.4244/EIJV8I9A162

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document

Kappetein A, Head S, Généreux P, Piazza N, Van Mieghem N, Blackstone E, Brott T, Cohen D, Cutlip D, Van Es G-A, Hahn R, Kirtane A, Krucoff M, Kodali SK, Mack M, Mehran R, Rodés-Cabau J, Vranckx P, Webb J, Windecker S, Serruys P, Leon M

November 20, 2012 | 10.4244/EIJV8I7A121

Clinical event committees in coronary stent trials: insights and recommendations based on experience in an unselected study population

Vranckx P, McFadden E, Mehran R, Cutlip D

July 27, 2012 | 10.4244/EIJV8I3A56

Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction

Vranckx P, Campo G, Anselmi M, Bolognese L, Colangelo S, Biondi-Zoccai G, Moreno R, Piva T, Favero L, Prati F, Nazzaro M, Fern J, Ferrari R, Valgimigli M

May 15, 2012 | 10.4244/EIJV8I1A12

Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe

Vranckx P, Boersma E, Garg S, Valgimigli M, Van Es G-A, Goedhart D, Serruys P

November 30, 2011 | 10.4244/EIJV7I7A134

Looking back into the future: desirudin in acute coronary syndromes and coronary stenting

Vranckx P, Valgimigli M, Serruys P

June 30, 2011 | 10.4244/EIJV7I2A42

Pascal Vranckx

Latest news